![PDF) Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs) PDF) Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs)](https://i1.rgstatic.net/publication/338905516_Targeting_CD38-Expressing_Multiple_Myeloma_and_Burkitt_Lymphoma_Cells_In_Vitro_with_Nanobody-Based_Chimeric_Antigen_Receptors_Nb-CARs/links/5e322cdf92851c7f7f0c252d/largepreview.png)
PDF) Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs)
![Tuberculostearic Acid-Containing Phosphatidylinositols as Markers of Bacterial Burden in Tuberculosis | ACS Infectious Diseases Tuberculostearic Acid-Containing Phosphatidylinositols as Markers of Bacterial Burden in Tuberculosis | ACS Infectious Diseases](https://pubs.acs.org/cms/10.1021/acsinfecdis.2c00075/asset/images/large/id2c00075_0007.jpeg)
Tuberculostearic Acid-Containing Phosphatidylinositols as Markers of Bacterial Burden in Tuberculosis | ACS Infectious Diseases
![PDF) Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies PDF) Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies](https://i1.rgstatic.net/publication/331462185_Nanobody_Targeting_of_Epidermal_Growth_Factor_Receptor_EGFR_Ectodomain_Variants_Overcomes_Resistance_to_Therapeutic_EGFR_Antibodies/links/5e8452fc92851c2f5270f57a/largepreview.png)